US-based Nektar Therapeutics has signed a definitive agreement to divest its Huntsville, Alabama manufacturing facility and ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Piper Sandler initiated coverage of Nektar (NKTR) with an Overweight rating and $7 price target The analyst believes Nektar’s lead asset ...

Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.

Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have been given an average rating of “Hold” by the six brokerages that are currently covering the stock, Marketbeat Ratings reports.

Short interest in Nektar Therapeutics (NASDAQ:NKTR) decreased during the last reporting period, falling from 7.76M to 7.31M. This put 5.08% of the company's publicly available shares short.

It is wholly-owned by Nektar Therapeutics. This press release contains forward-looking statements which can be identified by words such as: "will," "can," "expect," "develop," "potential," "advance," ...